Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free PRTC Stock Alerts

PureTech Health (PRTC) Financials

PureTech Health logo
$17.42 0.00 (0.00%)
As of 07/29/2026
Compare
Annual Income Statements for PureTech Health

Annual Income Statements for PureTech Health

This table shows PureTech Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -78 427 14 -165 -175 -155 275 -404
Consolidated Net Income / (Loss)		 -71 366 17 -213 -201 -153 326 -403
Net Income / (Loss) Continuing Operations		 -78 427 17 -163 -201 -153 326 -403
Total Pre-Tax Income 		-75 540 19 -163 -257 -123 322 -404
Total Operating Income		 -101 -131 -157 -342 -417 -228 176 -397
Total Gross Profit		 24 14 -26 -170 -166 -186 155 -328
Total Revenue		 24 14 -26 -170 -65 -54 48 -109
Operating Revenue		 24 14 -26 -170 -73 -53 47 -110
Other Revenue		 -0.28 0.04 - - 8.13 -0.91 0.96 1.33
Total Cost of Revenue		 0.00 0.00 0.00 0.00 101 131 -107 219
Operating Cost of Revenue		 - - - - 101 131 -107 219
Total Operating Expenses		 125 145 131 172 252 42 -21 68
Selling, General & Admin Expense		 47 59 49 57 61 53 71 47
Research & Development Expense		 77 86 82 110 152 96 69 57
Other Operating Expenses / (Income)		 - - - 4.77 30 -108 -162 -35
Total Other Income / (Expense), net		 26 671 174 179 160 105 147 -7.35
Interest Expense		 - - - - -28 10 7.86 42
Interest & Investment Income		 - - 173 - 105 53 2.63 35
Other Income / (Expense), net		 26 671 1.04 179 27 62 152 0.00
Income Tax Expense		 2.22 112 - - -56 31 -4.01 -0.84
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 2.83 2.15 -27 1.86 51 0.69
Basic Earnings per Share		 - - $0.02 - ($0.18) ($0.24) $0.21 ($0.46)
Weighted Average Basic Shares Outstanding		 - - 285.89M 287.80M 278.57M 271.85M 239.42M 241.68M
Diluted Earnings per Share		 - - $0.02 - ($0.18) ($0.24) $0.21 ($0.46)
Weighted Average Diluted Shares Outstanding		 - - 285.89M 287.80M 278.57M 271.85M 239.42M 241.68M
Weighted Average Basic & Diluted Shares Outstanding		 - - 285.89M 287.80M 278.57M 271.85M 239.42M 241.68M

Quarterly Income Statements for PureTech Health

No quarterly income statements for PureTech Health are available.

Annual Cash Flow Statements for PureTech Health

This table details how cash moves in and out of PureTech Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 44 29 272 34 -316 38 77 -48
Net Cash From Operating Activities		 -73 -75 -132 34 -105 -8.78 33 -110
Net Cash From Continuing Operating Activities		 -79 -75 -133 34 -105 -8.78 33 -110
Net Income / (Loss) Continuing Operations		 -71 366 4.57 -63 0.00 -67 28 -110
Consolidated Net Income / (Loss)		 -71 366 4.57 -63 - -67 28 -110
Depreciation Expense		 2.78 6.67 6.65 7.29 - 4.93 3.57 3.35
Non-Cash Adjustments To Reconcile Net Income		 -16 -448 -133 91 -105 9.23 52 4.36
Changes in Operating Assets and Liabilities, net		 5.03 0.19 -11 -1.41 - 44 -51 -7.61
Net Cash From Investing Activities		 -40 104 364 0.00 -201 66 49 62
Net Cash From Continuing Investing Activities		 -40 104 364 0.00 -201 66 49 62
Purchase of Property, Plant & Equipment		 -4.37 - 345 - -2.18 -0.07 -0.01 -0.01
Purchase of Investments		 -170 -70 -11 0.00 -249 -179 -309 -84
Sale of Property, Plant & Equipment		 0.13 - 0.00 - 0.00 0.87 0.26 0.27
Sale and/or Maturity of Investments		 148 174 30 0.00 50 245 357 145
Net Cash From Financing Activities		 157 0.00 39 0.00 -30 -20 -4.79 0.00
Net Cash From Continuing Financing Activities		 152 0.00 52 0.00 -11 -20 -4.79 0.00
Repayment of Debt		 -0.19 - -2.91 0.00 15 0.00 0.00 0.00
Repurchase of Common Equity		 -0.04 - - - -26 -20 -4.79 0.00
Cash Interest Received		 - 3.65 - 0.21 - 14 24 14

Quarterly Cash Flow Statements for PureTech Health

No quarterly cash flow statements for PureTech Health are available.

Annual Balance Sheets for PureTech Health

This table presents PureTech Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 941 990 946 703 694 603 535
Total Current Assets		 169 414 502 386 347 386 305
Cash & Equivalents		 132 404 466 150 191 281 252
Restricted Cash		 - - - - 1.63 1.64 1.60
Accounts Receivable		 1.98 2.56 3.17 12 2.38 1.52 1.76
Prepaid Expenses		 1.95 5.41 11 12 4.31 4.40 6.58
Current Deferred & Refundable Income Taxes		 - 0.00 4.51 10 12 0.00 6.37
Plant, Property, & Equipment, net		 21 23 27 23 9.54 7.07 5.20
Plant, Property & Equipment, gross		 21 23 27 - 9.54 7.07 5.20
Total Noncurrent Assets		 753 555 420 296 14 11 6.46
Long-Term Investments		 11 0.00 0.00 26 3.19 2.40 0.00
Other Noncurrent Operating Assets		 740 552 417 268 11 8.54 6.46
Total Liabilities & Shareholders' Equity		 941 990 946 703 694 603 535
Total Liabilities		 291 336 362 155 236 195 229
Total Current Liabilities		 139 181 226 67 51 41 46
Accounts Payable		 20 22 36 55 44 27 23
Current Deferred & Payable Income Tax Liabilities		 - - - - 0.00 0.08 1.21
Other Current Liabilities		 3.44 3.99 3.95 4.97 3.39 3.58 3.58
Total Noncurrent Liabilities		 152 156 136 61 184 153 183
Capital Lease Obligations		 35 32 29 24 18 15 11
Other Noncurrent Operating Liabilities		 109 127 181 4.18 3.70 4.11 4.92
Total Equity & Noncontrolling Interests		 650 654 584 575 458 408 306
Total Preferred & Common Equity		 668 654 594 570 464 415 312
Preferred Stock		 288 289 289 27 290 290 290
Total Common Equity		 668 670 594 542 174 124 22
Common Stock		 5.41 5.42 5.44 5.46 5.46 4.86 4.86
Retained Earnings		 254 260 200 150 84 32 -77
Treasury Stock		 - - 0.00 -26 -45 -47 -41
Other Equity Adjustments		 120 115 99 414 129 134 135
Noncontrolling Interest		 -18 -16 -9.37 5.37 -5.84 -6.77 -6.40

Quarterly Balance Sheets for PureTech Health

No quarterly balance sheets for PureTech Health are available.

Annual Metrics And Ratios for PureTech Health

This table displays calculated financial ratios and metrics derived from PureTech Health's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 239,421,312.00 241,684,038.00
DEI Adjusted Shares Outstanding		 - - - - - - 239,421,312.00 241,684,038.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 1.15 -1.67
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% -40.37% -283.52% -551.13% 155.07% -80.28% 187.61% -327.97%
EBITDA Growth		 0.00% 852.63% -127.40% -3.95% 31.72% 85.00% 305.82% -218.79%
EBIT Growth		 0.00% 816.05% -128.97% -4.20% 34.77% 80.36% 297.54% -221.11%
NOPAT Growth		 0.00% -46.78% -51.74% -52.22% 61.35% 84.86% 211.65% -256.10%
Net Income Growth		 0.00% 618.07% -95.35% -1,352.23% -10.27% 71.63% 312.55% -223.56%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 187.50% -319.05%
Operating Cash Flow Growth		 0.00% -3.25% -75.39% 126.07% -406.64% 47.15% 470.79% -437.69%
Free Cash Flow Firm Growth		 0.00% 0.00% 105.37% -315.36% -150.54% 145.66% -14.09% -325.48%
Invested Capital Growth		 0.00% 0.00% -37.10% -52.06% 55.70% -39.68% 79.61% 50.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 324.66% 0.00%
EBITDA Margin		 -304.67% 3,845.56% 0.00% 0.00% -113.65% -86.44% 694.91% 0.00%
Operating Margin		 -423.62% -922.00% 0.00% 0.00% -141.46% -108.63% 368.74% 0.00%
EBIT Margin		 -316.33% 3,798.65% 0.00% 0.00% -113.65% -113.20% 687.41% 0.00%
Profit (Net Income) Margin		 -296.54% 2,576.47% 0.00% 0.00% -251.22% -361.44% 684.84% 0.00%
Tax Burden Percent		 93.74% 67.83% 89.67% 130.75% 221.04% 319.28% 101.24% 99.79%
Interest Burden Percent		 100.00% 100.00% -12.13% 100.00% 100.00% 100.00% 98.40% 101.85%
Effective Tax Rate		 0.00% 20.83% 0.00% 0.00% 0.00% 0.00% -1.24% 0.00%
Return on Invested Capital (ROIC)		 0.00% -40.39% 0.00% 0.00% -46.77% -7.25% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -726.89% 0.00% 0.00% -9.48% 9.01% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 152.96% 0.00% 0.00% 6.24% -5.64% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 112.57% 2.61% -34.42% -40.53% -12.90% 75.33% -112.97%
Cash Return on Invested Capital (CROIC)		 0.00% -240.39% 7.92% -29.87% -90.33% 42.25% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 57.34% 0.00% 0.00% -12.89% -2.99% 50.51% 0.00%
Return on Assets (ROA)		 0.00% 38.89% 0.00% 0.00% -28.49% -9.54% 50.32% 0.00%
Return on Common Equity (ROCE)		 0.00% 115.62% 2.68% -35.13% -39.71% -12.56% 25.94% -23.15%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 54.80% 2.60% -35.89% -41.24% -14.35% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -71 -104 -157 -240 -93 -14 178 -278
NOPAT Margin		 -296.53% -729.97% 0.00% 0.00% -99.02% -76.04% 373.32% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 686.50% 74.62% 6.99% -37.29% -16.27% 31.43% -34.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - 42.08% -87.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -224.66% 0.00%
SG&A Expenses to Revenue		 198.78% 417.78% 0.00% 0.00% 65.24% 289.11% 150.03% 0.00%
R&D to Revenue		 324.84% 604.22% 0.00% 0.00% 163.04% 522.05% 145.80% 0.00%
Operating Expenses to Revenue		 523.62% 1,022.00% 0.00% 0.00% 241.46% 208.63% -44.08% 0.00%
Earnings before Interest and Taxes (EBIT)		 -75 540 -156 -163 -106 -21 327 -397
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -73 546 -150 -156 -106 -16 331 -393
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.78 1.69 1.69 4.03 18.27
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.79 1.70 1.69 4.03 18.27
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 9.82 42.58 10.53 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 1.83 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.75% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 5.95 2.56 3.21 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 6.60 25.30 10.82 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 1.56 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 1.57 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 2.90 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 26.80 0.00 0.00 15.82 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 5.71 4.09 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.06 0.11 0.08 0.07 0.05 0.04 0.04
Long-Term Debt to Equity		 0.00 0.06 0.11 0.08 0.06 0.05 0.04 0.04
Financial Leverage		 0.00 -0.21 -0.36 -0.61 -0.66 -0.63 -1.09 -1.03
Leverage Ratio		 0.00 1.45 1.48 1.56 1.42 1.35 1.50 1.59
Compound Leverage Factor		 0.00 1.45 -0.18 1.56 1.42 1.35 1.47 1.62
Debt to Total Capital		 0.00% 5.30% 10.09% 7.71% 6.79% 4.57% 3.47% 3.50%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 5.30% 10.09% 7.71% 5.96% 4.57% 3.47% 3.50%
Preferred Equity to Total Capital		 0.00% 41.93% 39.75% 45.71% 4.43% 0.04% 68.68% 91.63%
Noncontrolling Interests to Total Capital		 0.00% -2.57% -2.23% -1.48% 0.87% -1.21% -1.60% -2.02%
Common Equity to Total Capital		 0.00% 97.27% 92.14% 93.77% 87.90% 96.61% 29.45% 6.89%
Debt to EBITDA		 0.00 0.07 -0.49 -0.31 -0.39 -1.38 0.04 -0.03
Net Debt to EBITDA		 0.00 -0.25 2.21 2.68 3.14 19.64 -0.82 0.62
Long-Term Debt to EBITDA		 0.00 0.07 -0.49 -0.31 -0.35 -1.38 0.04 -0.03
Debt to NOPAT		 0.00 -0.35 -0.47 -0.20 -0.45 -1.57 0.08 -0.04
Net Debt to NOPAT		 0.00 1.32 2.10 1.74 3.61 22.33 -1.52 0.88
Long-Term Debt to NOPAT		 0.00 -0.35 -0.47 -0.20 -0.40 -1.57 0.08 -0.04
Altman Z-Score		 0.00 0.00 0.00 1.65 4.03 2.61 4.18 -1.23
Noncontrolling Interest Sharing Ratio		 0.00% -2.71% -2.60% -2.07% 2.01% 2.62% 65.57% 79.50%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 1.21 2.29 2.22 5.75 7.31 9.33 6.59
Quick Ratio		 0.00 1.18 2.25 2.07 5.39 6.94 6.82 5.49
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -617 33 -71 -179 82 126 -284
Operating Cash Flow to CapEx		 -1,716.89% 0.00% 0.00% 0.00% -4,842.33% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 16.05 -6.74
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 4.14 -2.61
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 4.18 -2.60
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.02 0.00 0.00 0.11 0.03 0.07 0.00
Accounts Receivable Turnover		 0.00 7.19 0.00 0.00 12.43 2.59 24.44 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.66 0.00 0.00 3.76 1.13 5.74 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.74
Days Sales Outstanding (DSO)		 0.00 50.79 0.00 0.00 29.36 141.01 14.93 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.75
Cash Conversion Cycle (CCC)		 0.00 50.79 0.00 0.00 29.36 141.01 14.93 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 514 323 155 241 145 -13 -6.52
Invested Capital Turnover		 0.00 0.06 0.00 0.00 0.47 0.10 -1.22 0.00
Increase / (Decrease) in Invested Capital		 0.00 514 -191 -168 86 -96 52 6.73
Enterprise Value (EV)		 0.00 0.00 0.00 921 617 466 515 439
Market Capitalization		 0.00 0.00 0.00 1,058 918 785 502 398
Book Value per Share		 $0.00 $0.00 $2.34 $2.08 $1.88 $1.67 $0.46 $0.09
Tangible Book Value per Share		 $0.00 $0.00 $2.34 $2.07 $1.88 $1.66 $0.46 $0.09
Total Capital		 0.00 687 727 633 617 480 423 317
Total Debt		 0.00 36 73 49 42 22 15 11
Total Long-Term Debt		 0.00 36 73 49 37 22 15 11
Net Debt		 0.00 -137 -331 -417 -334 -313 -270 -243
Capital Expenditures (CapEx)		 4.24 0.00 -345 0.00 2.18 0.00 -0.24 -0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -133 -170 -190 -26 -27 63 4.64
Debt-free Net Working Capital (DFNWC)		 0.00 30 233 276 324 300 345 259
Net Working Capital (NWC)		 0.00 30 233 276 319 300 345 259
Net Nonoperating Expense (NNE)		 0.00 -470 -174 -27 142 53 -148 125
Net Nonoperating Obligations (NNO)		 0.00 -137 -331 -429 -334 -313 -421 -312
Total Depreciation and Amortization (D&A)		 2.78 6.67 6.65 7.29 0.00 4.93 3.57 3.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -934.71% 0.00% 0.00% -27.70% -148.87% 131.38% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 208.64% 0.00% 0.00% 346.75% 1,625.80% 723.95% 0.00%
Net Working Capital to Revenue		 0.00% 208.64% 0.00% 0.00% 341.24% 1,625.80% 723.95% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.02 $0.00 $0.00 $0.00 $0.21 ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 285.89M 0.00 278.57M 271.85M 239.42M 241.68M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.02 $0.00 $0.00 $0.00 $0.21 ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 285.89M 0.00 278.57M 271.85M 239.42M 241.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.02 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 285.89M 0.00 278.57M 271.85M 239.42M 241.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -71 -104 -110 -240 -87 -14 123 -278
Normalized NOPAT Margin		 -296.53% -729.97% 0.00% 0.00% -92.74% -76.04% 258.12% 0.00%
Pre Tax Income Margin		 -316.33% 3,798.65% 0.00% 0.00% -113.65% -113.20% 676.43% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 41.67 -9.40
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 22.63 -6.58
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 41.70 -9.39
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 22.66 -6.57
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.05% 0.00% 0.00% 0.00% -11.28% 0.00% 1.47% 0.00%

Quarterly Metrics And Ratios for PureTech Health

No quarterly metrics and ratios for PureTech Health are available.


Financials Breakdown Chart

PureTech Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PureTech Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

PureTech Health's net income appears to be on an upward trend, with a most recent value of -$403.08 million in 2025, rising from -$70.66 million in 2018. The previous period was $326.24 million in 2024. Check out PureTech Health's forecast to explore projected trends and price targets.

PureTech Health's total operating income in 2025 was -$396.57 million, based on the following breakdown:
  • Total Gross Profit: -$328.08 million
  • Total Operating Expenses: $68.50 million

Over the last 7 years, PureTech Health's total revenue changed from $23.83 million in 2018 to -$108.60 million in 2025, a change of -555.8%.

PureTech Health's total liabilities were at $229.03 million at the end of 2025, a 17.6% increase from 2024, and a 21.2% decrease since 2019.

In the past 6 years, PureTech Health's cash and equivalents has ranged from $132.36 million in 2019 to $465.71 million in 2021, and is currently $252.47 million as of their latest financial filing in 2025.

Over the last 7 years, PureTech Health's book value per share changed from 0.00 in 2018 to 0.09 in 2025, a change of 9.1%.


Related Companies

Financial statements for NASDAQ:PRTC last updated on 7/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel